<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916197</url>
  </required_header>
  <id_info>
    <org_study_id>00375929</org_study_id>
    <nct_id>NCT04916197</nct_id>
  </id_info>
  <brief_title>Effect of Prolonged Sedation With Dexmedetomidine on Long-term Prognosis of Patients With Acute Ischemic Stroke After Mechanical Thrombectomy</brief_title>
  <official_title>Effect of Prolonged Sedation With Dexmedetomidine on Long-term Prognosis of Patients With Acute Ischemic Stroke After Mechanical Thrombectomy: a Single Center, Prospective, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dexmedetomidine can attenuate the activity of sympathetic nervous system under stress&#xD;
      response and improve ischemia-reperfusion injury. The investigators hypothesized that the&#xD;
      prolonged sedation of dexmedetomidine after thrombectomy may improve the clinical outcome of&#xD;
      acute ischemic stroke patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endovascular treatment with mechanical thrombectomy is the standard treatment for acute large&#xD;
      vessel occlusion.&#xD;
&#xD;
      Dexmedetomidine is a commonly used sedative in mechanical thrombectomy of acute ischemic&#xD;
      stroke.&#xD;
&#xD;
      Dexmedetomidine can attenuate the activity of sympathetic nervous system under stress&#xD;
      response and improve ischemia-reperfusion injury.&#xD;
&#xD;
      The investigators hypothesized that the prolonged sedation of dexmedetomidine after&#xD;
      thrombectomy may improve the clinical outcome of acute ischemic stroke patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The good prognosis rate</measure>
    <time_frame>90 days after operation</time_frame>
    <description>Modified Rankin Scale ≤ 2 points. mRS range from 0 to 5, higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified thrombolysis in cerebral infarction score</measure>
    <time_frame>Immediately after operation</time_frame>
    <description>Evaluate the recanalization after mechanical thrombectomy. mTICI range from 0 to 3, higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of National Institute of Health stroke scale</measure>
    <time_frame>24 hours after operation</time_frame>
    <description>NIHSS admission - NIHSS 24 hours. Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of National Institute of Health stroke scale</measure>
    <time_frame>on the 7th day after surgery or discharged day, up to 30 days</time_frame>
    <description>NIHSS admission - NIHSS 7th day or discharged day.Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of ischemic penumbra</measure>
    <time_frame>on the 7th day after surgery or discharged day, up to 30 days</time_frame>
    <description>The difference of infarct volume between preoperative and 7th day or discharged day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>From the date of admission until discharged from ICU, up to 30 days</time_frame>
    <description>Length of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>From the date of admission until discharged from hospital, up to 30 days</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-stroke cognitive impairment rate</measure>
    <time_frame>90 days after operation</time_frame>
    <description>Evaluate by Chinese version of telephone interview for cognitive status-modified.Tics-m range from 0 to 60, higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-stroke depression rate</measure>
    <time_frame>90 days after operation</time_frame>
    <description>Evaluate by Patient Health Questionnaire（PHQ-9）followed up by telephone, range from 0 to 27, higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine prolonged group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine 0.1~1.0 μg/kg/h for 24h after patients finished mechanical thrombectomy and returned to ICU. Maintain Ramsay score 2-3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo（Equal dose of saline）24h after patients finished mechanical thrombectomy and returned to ICU. If Ramsay Sedation score was 1, midazolam was given 0.02 ~ 0.1mg/kg. If the dose of midazolam was more than 0.2mg/kg within 1 hour after operation, the Ramsay Sedation score was still 1, propofol was given to maintain sedation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine prolonged group</intervention_name>
    <description>Dexmedetomidine for 24h after patients finished mechanical thrombectomy and returned to ICU.</description>
    <arm_group_label>Dexmedetomidine prolonged group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>Placebo（Equal dose of saline）24h after patients finished mechanical thrombectomy and returned to ICU.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NIHSS≤25&#xD;
&#xD;
          -  mRS score before stroke was less than 3&#xD;
&#xD;
          -  Acute ischemic stroke (including anterior circulation)&#xD;
&#xD;
          -  mTICI rate 2b or 3&#xD;
&#xD;
          -  According to the 2018 AHA/ASA guidelines for the management of acute ischemic stroke,&#xD;
             patients who plan to receive mechanical thrombectomy under local anesthesia and&#xD;
             sedation&#xD;
&#xD;
          -  Informed consent was signed by patient or legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intracerebral hemorrhage occurred in the responsible vessel area in the past 6 weeks&#xD;
&#xD;
          -  Patients who had received stent treatment at the responsible vessel in the past&#xD;
&#xD;
          -  Neurological function was restored at or before angiography&#xD;
&#xD;
          -  Patients who are allergic to heparin, aspirin, clopidogrel, rapamycin, lactic acid&#xD;
             polymer, poly (n-butyl methacrylate), stainless steel, anesthetics and contrast agents&#xD;
             or have contraindications&#xD;
&#xD;
          -  Hemoglobin was less than 70g/L, platelet count was less than 50×109/L, international&#xD;
             normalized ratio (INR) greater than 1.5 (irreversible), there are uncorrectable&#xD;
             bleeding factors&#xD;
&#xD;
          -  Blood glucose &lt; 2.7 mmol/L or &gt; 22.2 mmol/L&#xD;
&#xD;
          -  Severe liver or kidney disfunction, ALT&gt;3 times the upper limit of normal value or&#xD;
             AST&gt;3 times the upper limit of normal value, creatinine&gt;1.5 times the upper limit of&#xD;
             normal value&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Previous history of mental illness&#xD;
&#xD;
          -  Stroke with other acute diseases or postoperative stroke of other operation&#xD;
&#xD;
          -  Heart rate less than 50bpm, second or third degree of atrioventricular block (except&#xD;
             for pacemaker implantation), systolic blood pressure less than 90mmHg (two vasoactive&#xD;
             drugs were already infused continuously )&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lina Yang</last_name>
    <phone>18611635556</phone>
    <email>Thoth_safin@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chao Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Yang</last_name>
      <phone>18611635556</phone>
      <email>Thoth_safin@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Changwei Wei</investigator_full_name>
    <investigator_title>Deputy chief physician</investigator_title>
  </responsible_party>
  <keyword>mechanical thrombectomy</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Modified Rankin Scale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

